Cargando…
Recent Strategic Advances in CFTR Drug Discovery: An Overview
Cystic fibrosis transmembrane conductance regulator (CFTR)-rescuing drugs have already transformed cystic fibrosis (CF) from a fatal disease to a treatable chronic condition. However, new-generation drugs able to bind CFTR with higher specificity/affinity and to exert stronger therapeutic benefits a...
Autores principales: | Rusnati, Marco, D’Ursi, Pasqualina, Pedemonte, Nicoletta, Urbinati, Chiara, Ford, Robert C., Cichero, Elena, Uggeri, Matteo, Orro, Alessandro, Fossa, Paola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177952/ https://www.ncbi.nlm.nih.gov/pubmed/32244346 http://dx.doi.org/10.3390/ijms21072407 |
Ejemplares similares
-
Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing
por: Fossa, Paola, et al.
Publicado: (2022) -
An Update on CFTR Drug Discovery: Opportunities and Challenges
por: D’Ursi, Pasqualina, et al.
Publicado: (2022) -
Heparin and heparan sulfate proteoglycans promote HIV-1 p17 matrix protein oligomerization: computational, biochemical and biological implications
por: Bugatti, Antonella, et al.
Publicado: (2019) -
Speeding Up the Identification of Cystic Fibrosis Transmembrane Conductance Regulator-Targeted Drugs: An Approach Based on Bioinformatics Strategies and Surface Plasmon Resonance
por: Rusnati, Marco, et al.
Publicado: (2018) -
Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics
por: D'Ursi, Pasqualina, et al.
Publicado: (2016)